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Abstract
We investigated the link between renal function as evaluated by estimated glomerular filtration
rate (eGFR) and metabolic syndrome in Japanese. A total of 11,711 Japanese subjects, aged 20-
79 years, were recruited in a cross-sectional clinical investigation. From this group, we further
investigated the data on 1,576 subjects. eGFR was calculated using serum creatinine (Cr), age and
sex. The diagnosis of metabolic syndrome was based on the Japanese criteria. In the first analysis,
288 men (7.8%) and 498 women (6.2%) were diagnosed with reduced eGFR (<60ml/min). eGFR
was not correlated with anthropometric, body composition parameters in either sex. In the second
analysis, in subjects without medications, 132 men (20.8%) and 15 women (1.6%) were diagnosed
with metabolic syndrome. eGFR was lower in men with abdominal obesity and in women with
hypertension was than in those without. Among Japanese not taking medications, lower eGFR
may be a characteristic of men with abdominal obesity and of women with hypertension.
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We investigated the link between renal function as evaluated by estimated glomerular ﬁltration rate 
(eGFR) and metabolic syndrome in Japanese.  A total of 11,711 Japanese subjects,  aged 20-79 years,  
were recruited in a cross-sectional clinical investigation.  From this group,  we further investigated the 
data on 1,576 subjects.  eGFR was calculated using serum creatinine (Cr),  age and sex.  The diagnosis 
of metabolic syndrome was based on the Japanese criteria.  In the ﬁrst analysis,  288 men (7.8ｵ) and 
498 women (6.2ｵ) were diagnosed with reduced eGFR (＜60ml/min).  eGFR was not correlated with 
anthropometric,  body composition parameters in either sex.  In the second analysis,  in subjects with-
out medications,  132 men (20.8ｵ) and 15 women (1.6ｵ) were diagnosed with metabolic syndrome.  
eGFR was lower in men with abdominal obesity and in women with hypertension was than in those 
without.  Among Japanese not taking medications,  lower eGFR may be a characteristic of men with 
abdominal obesity and of women with hypertension.
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hronic kidney disease (CKD) has become an 
important public health challenge in Japan and 
is a major risk factor for end-stage renal disease,  
cardiovascular disease and premature death [1,  2].  
Identifying and treating risk factors for early chronic 
kidney disease may be the best approach to preventing 
and delaying adverse outcomes [1].  In Japan,  clinical 
practice guidelines established by the Japanese 
Society of Nephrology estimate that 18.7ｵ of adults 
have CKD,  which is deﬁned as kidney damage or a 
glomerular ﬁltration rate (GFR) ＜60ml/min/1.73m2 
for at least 3 months regardless of cause [3],  and 
that 4.1ｵ have moderate or severe CKD [4].
　 Metabolic syndrome is characterized by abdominal 
obesity,  high blood pressure,  dyslipidemia and 
impaired glucose tolerance [5].  In Japan,  according 
to the criteria for this syndrome as deﬁned in April 
2005,  30.7ｵ of men and 3.6ｵ of women have meta-
bolic syndrome [6,  7].  In some studies,  CKD is 
closely related to body composition parameters and 
metabolic syndrome [8-18].  However,  the link 
between renal function evaluated by estimated GFR 
(eGFR) and metabolic syndrome components using the 
Japanese criteria remains to be investigated.
　 In this study,  we investigated renal function evalu-
ated by eGFR in Japanese and evaluated the clinical 
impact of metabolic syndrome on eGFR in subjects not 
taking medications.
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Subjects and Methods
　 Subjects. In the ﬁrst analysis,  we used all data 
on 11,711 Japanese (3,674 men and 8,037 women) 
aged 20-79 years in a cross-sectional study.  All sub-
jects met the following criteria: (1) they had been 
wanting to change their lifestyle i.e.,  diet and exercise 
habits,  and had received an annual health checkup 
from June 1997 to May 2007 at Okayama Southern 
Institute of Health; (2) their creatinine (Cr) and 
anthropometric measurements had been taken as part 
of their annual health checkups; and (3) they provided 
informed consent (Table 1).
　 In the second analysis,  among the 11,711 subjects,  
we further examined the data on 1,576 subjects (636 
men and 940 women) who undertook fasting blood 
examination and blood pressure measurements and who 
were currently taking no medications; we also exam-
ined the Cr and anthropometric measurements of these 
second-analysis subjects (Table 2).  In addition,  medi-
cal staﬀ subjectively evaluated these subjectsʼ life-
styles,  and encouraged subjects with fasting plasma 
glucose≧126mg/dl to begin taking medication.
　 The study was approved by the Ethics Committee 
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Table 1　 Clinical proﬁles of subjects in the ﬁrst analysis
Men (n＝3,674) Women (n＝8,037)
Mean±SD Minimum Maximum Mean±SD Minimum Maximum
Age  43.8±14.2 20 79  42.9±14.1 20 79
Height (cm) 168.9±6.2 143.7 187.6 156.2±5.7 134.9 179.3
Body weight (kg)  70.3±11.7  39.1 175.7  55.1±9.0  32.1 116.9
BMI (kg/m2)  24.6±3.7  13.6  61.5  22.6±3.6  12.9 48.7
Body fat percentage (%)  24.3±6.7 　1.2  47.9  30.7±7.0 　3.9 56.2
Abdominal circumference (cm)  84.3±10.2  58.0 157.0  72.3±9.7  43.3 123.6
Hip circumference (cm)  94.2±6.3  71.0 145.5  91.0±6.0  58.5 132.0
Cr (mg/dl)  0.83±0.15  0.39  2.57  0.61±0.21  0.20 8.63
eGFR (ml/min/1.73m2)  84.8±18.7  20.2 191.3  90.6±22.7 　4.3 260.0
BMI: body mass index
Cr: creatinine
eGFR: estimated glomerular ﬁltration rate
Table 2　 Clinical proﬁles of subjects in the second analysis
Men (n＝636) Women (n＝940)
Mean±SD Minimum Maximum Mean±SD Minimum Maximum
Age 43.8±11.2 20 78 45.7±11.6 20 76
Height (cm) 169.1±6.0 146.9 187.6 156.7±5.5 139.3 176.3
Body weight (kg) 71.5±11.2  40.1 121.7 56.0±8.9 37.1 105.3
BMI (kg/m2) 25±3.5  16.4  43.3 22.8±3.5 15.7 41.3
Body fat percentage (%) 24.4±6.3 　2.2  41.3 31.1±6.6 10.6 50.1
Abdominal circumference (cm) 84.7±9.5  58.8 123.0 72.5±9.0 55.5 115.6
Hip circumference (cm) 94.9±5.8  79.1 121.0 91.3±6.1 60.0 122.0
Cr (mg/dl) 0.83±0.14  0.50  1.85 0.62±0.12 0.36 1.10
eGFR (ml/min/1.73m2) 84.0±16.8  36.0 146.5 84.5±18.7 38.3 166.8
Systolic blood pressure (mmHg) 129.6±15.7  90.0 205.0 121.3±16.4 88.0 193.0
Diastolic blood pressure (mmHg) 81.2±11.1  33.0 131.0 75.2±10.2 44.0 120.0
Triglyceride (mg/dl) 142.5±116.8  29.0 1,683.0 93.6±14.7 70.0 331.0
HDL cholesterol (mg/dl) 55.4±14.6  18.0 120.0 67.2±16.4 28.0 151.0
Blood sugar (mg/dl) 100.6±16.8  63.0 218.0 93.6±14.7 70.0 331.0
BMI: body mass index
Cr: creatinine
eGFR: estimated glomerular ﬁltration rate
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of Okayama Health Foundation.
　 Anthropometric and body composition mea-
surements. The anthropometric parameters were 
evaluated by using the following respective parame-
ters such as height,  body weight,  body mass index 
(BMI),  abdominal circumference,  and hip circumfer-
ence.  BMI was calculated by weight/[height]2 (kg/
m2).  The abdominal circumference was measured at the 
umbilical level and the hip was measured at the widest 
circumference over the trochanter in standing subjects 
after normal expiration [19].  Body fat percentage 
was measured by an air displacement plethysmograph 
called the BOD POD Body Composition System (Life 
Measurement Instruments,  Concord,  CA,  USA) [20,  
21].
　 Blood pressure measurements. Each par-
ticipantʼs blood pressure was measured after resting 
at least 15min in the sitting position.
　 Blood sampling and assays. The level of Cr 
was measured with an automated biochemical analyzer 
(model 7700; HITACHI,  Tokyo,  Japan) and Accuras 
Auto CRE (Shino-Test Corporation,  Tokyo,  Japan).  
High-density lipoprotein (HDL) cholesterol [22],  
triglycerides (L Type Wako Triglyceride･H,  Wako 
Chemical,  Osaka,  Japan) and plasma glucose (hexoki-
nase method) were also measured at the Okayama 
Southern Institute of Health,  Okayama Health Foun-
dation.  The accuracy of the measurements was main-
tained during the study period.  eGFR was calculated 
using the following equation: eGFR (ml/min/1.73m2)
＝194×Cr－1.094×Age－0.287 (for men) and eGFR (ml/
min/1.73m2)＝194×Cr－1.094×Age－0.287×0.739 (for 
women) [23].  Reduced eGFR was deﬁned as an 
eGFR ＜60ml/min/1.73m2.
　 Deﬁnition of metabolic syndrome. The 
syndrome was deﬁned [6],  among men with an 
abdominal circumference in excess of 85cm and women 
with an abdominal circumference in excess of 90cm 
[24],  as having 2 or more of the following compo-
nents: 1) dyslipidemia: triglyceride≧150mg/dl and/
or HDL cholesterol＜40mg/dl; 2) hypertension:  
blood pressure≧130/85mmHg; 3) Impaired glucose 
toler ance: fasting plasma glucose≧110mg/dl.
　 Statistical analysis. Data are expressed as 
means ± standard deviation (SD) values.  A compari-
son of parameters between the 2 groups was made 
using the unpaired t-test and covariance analysis.  
Simple correlation analysis was performed as well to 
test for the signiﬁcance of the linear relationship 
among continuous variables: p＜0.05 was considered 
statistically signiﬁcant.  Statistical analysis was per-
formed with StatView 5.0 (SAS Institute Inc.,  Cary,  
NC,  USA).
Results
　 In the ﬁrst analysis,  the mean eGFR was 84.8±
18.7ml/min/1.73m2 in men and 90.6±22.7ml/min/ 
1.73m2 in women (Table 1).  A diagnosis of reduced 
eGFR was made for 288 men (7.8ｵ) and 498 women 
(6.2ｵ).  eGFR was not clearly correlated with anthro-
pometric,  body composition parameters in either sex 
(Table 3).  eGFR in men with abdominal obesity (81.8
±17.8ml/min/1.73m2) was lower than that in men 
without abdominal obesity (87.4±19.1ml/min/1.73m2),  
but the diﬀerence was not signiﬁcant after adjusting 
for age (p＝0.0675).  eGFR in women with abdominal 
obesity (83.8±22.2ml/min/1.73m2) was similar to 
that in women without abdominal obesity after adjust-
ing for age (91.0±22.6ml/min/1.73m2) (p＝0.8039).
　 In the second analysis,  we clariﬁed the prevalence 
of metabolic syndrome among subjects who were not 
taking without medications (Table 4).  Among the 
1,576 Japanese subjects,  306 men (48.1ｵ) had an 
abdominal circumference in excess of 85cm and 48 
women (5.1ｵ) had an abdominal circumference 
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Table 3　 Relationship between eGFR and anthropometric, body composition parameters
Men Women
r p r p
Body weight (kg) －0.017 　0.2929 －0.110 ＜0.0001
BMI (kg/m2) －0.086 ＜0.0001 －0.174 ＜0.0001
Body fat percentage (%) －0.146 ＜0.0001 －0.205 ＜0.0001
Abdominal circumference －0.142 ＜0.0001 －0.233 ＜0.0001
Hip circumference (cm) －0.006 　0.7210 －0.060 ＜0.0001
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exceeding 90cm.  In addition,  132 men (20.8ｵ) and 
only 15 women (1.6ｵ) were diagnosed with the syn-
drome.
　 In subjects not taking medications,  we also com-
pared eGFR levels between the groups with and 
without each component of the Japanese deﬁnition of 
metabolic syndrome (Table 4).  To avoid the inﬂuence 
of age,  we used age as a covariate and compared 
eGFR between Japanese with and those without meta-
bolic syndrome components using covariance analysis.  
eGFR in men with abdominal obesity and in women 
with hypertension was signiﬁcantly lower than in sub-
jects without these components of metabolic syndrome,  
even after adjusting for age.  However,  there were no 
signiﬁcant diﬀerences in eGFR between the groups 
with or without other components of metabolic syn-
drome.  In addition,  eGFR in subjects with metabolic 
syndrome was similar to that in subjects without it,  
even after adjusting for age.
Discussion
　 Obesity is a signiﬁcant risk factor for developing 
CKD and proteinuria [8-11].  Fox et al.  reported that 
the odds ratio (OR) for developing new-onset kidney 
disease,  deﬁned as a GFR ＜59.3ml/min/1.73m2 in 
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Table 4　 Comparison of eGFR between subjects with and without metabolic syndrome
Men Abdominal obesity (＋) Abdominal obesity (－) p p (Afrer adjusting for age)
Number of subjects 306 330
eGFR (ml/min/1.73m2) 83.8±14.9 84.1±18.4 0.7865 0.0055
Impaired glucose torelance (＋) Impaired glucose torelance (－)
Number of subjects 104 532
eGFR (ml/min/1.73m2) 86.9±16.4 83.4±16.8 0.0479 0.0880
Hypertension (＋) Hypertension (－)
Number of subjects 347 289
eGFR (ml/min/1.73m2) 82.7±16.0 85.5±17.6 0.0338 0.1106
Dyslipidemia (＋) Dyslipidemia (－)
Number of subjects 223 413
eGFR (ml/min/1.73m2) 83.1±16.6 84.4±16.9 0.3501 0.6986
Metabolic syndrome (＋) Metabolic syndrome (－)
Number of subjects 132 504
eGFR (ml/min/1.73m2) 83.6±15.7 84.1±17.1 0.7632 0.0830
Women Abdominal obesity (＋) Abdominal obesity (－)
Number of subjects 48 892
eGFR (ml/min/1.73m2) 84.8±16.7 84.5±18.8 0.9179 0.2654
Impaired glucose torelance (＋) Impaired glucose torelance (－)
Number of subjects 50 890
eGFR (ml/min/1.73m2) 86.0±18.1 84.4±18.8 0.5651 0.8745
Hypertension (＋) Hypertension (－)
Number of subjects 300 640
eGFR (ml/min/1.73m2) 80.6±17.0 86.3±19.3 ＜0.0001 0.0222
Dyslipidemia (＋) Dyslipidemia (－)
Number of subjects 108 832
eGFR (ml/min/1.73m2) 80.6±20.0 85.0±18.5 0.0223 0.2757
Metabolic syndrome (＋) Metabolic syndrome (－)
Number of subjects 15 925
eGFR (ml/min/1.73m2) 81.5±17.0 84.6±18.8 0.5297 0.1077
Mean±SD
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women and 64.3ml/min/m2 in men,  was 1.23,  repre-
senting a 23ｵ increase in BMI within 10 -years [8].  
In Japan,  it was also reported that BMI above 25kg/
m2 was linked to proteinuria [9].  Bonnet et al.  
reported that abdominal obesity was related to the 
development of elevated albuminuria in both sexes,  
suggesting that the measurement of abdominal circum-
ference might improve the identiﬁcation of non-dia-
betic individuals at risk of developing microalbuminu-
ria [10].  In addition,  a greater waist-to-hip ratio was 
associated with a greater risk for diminished ﬁltration,  
even when corrected for BMI [11].  In this study,  the 
relationships between eGFR and anthropometric,  body 
composition parameters were not clearly revealed in 
the ﬁrst analysis.  However,  after adjusting for age by 
using covariance analysis,  eGFR in men with abdomi-
nal obesity tended to be lower than that in men with-
out abdominal obesity in the ﬁrst and second analyses.  
Therefore,  we could not accurately prove a link 
between eGFR and anthropometric,  body composition 
parameters,  unlike the case in previous studies.
　 This study is the ﬁrst to reveal a relationship 
between eGFR and metabolic syndrome,  deﬁned by the 
new Japanese criteria of metabolic sundrome.  Meta-
bolic syndrome has important clinical and public health 
implications in Japan because it is a common disorder 
in that country [7].  Previous studies have docu-
mented that metabolic syndrome is an important risk 
factor for diabetes,  coronary heart disease and stroke 
[25-27].  The present study shows new and important 
information about the relationship between eGFR and 
metabolic syndrome in a large sample of Japanese.
　 Subjects with metabolic syndrome,  using the 
modiﬁed Adult Treatment Panel (ATP) III deﬁnition 
[28],  showed higher urinary albumin excretion and 
left ventricular mass index,  increased intima-media 
thickness,  and a higher prevalence of microalbuminu-
ria [12].  Compared with subjects with 0 or 1 compo-
nent of the metabolic syndrome,  subjects with 2,  3,  
4,  or 5 components of the syndrome had multivariate-
adjusted odds ratios of 2.21,  3.38,  4.23,  and 5.85 for 
CKD [13].  Using the Japanese criteria,  we previ-
ously reported that the prevalence of proteinuria in 
subjects with metabolic syndrome was signiﬁcantly 
higher than that in subjects without the syndrome 
[14].  Tanaka et al.  [15],  Ninomiya T et al.  [16] and 
Iseki et al.  [17] reported that metabolic syndrome,  
using the modiﬁed ATP III deﬁnition,  was associated 
with CKD in Japanese.  Although Tsuda et al.  [18] 
revealed that the level of microalbuminuria in subjects 
with metabolic syndrome according to the Japanese 
criteria was signiﬁcantly higher than that in subjects 
without the syndrome,  the link between eGFR and 
metabolic syndrome using the Japanese criteria has not 
been investigated until now.  In this study,  although we 
evaluated eGFR in subjects without medications,  the 
clinical impact of abdominal obesity in men and hyper-
tension in women was noted in the second analysis.  
However,  eGFR in subjects with metabolic syndrome 
was similar to that in subjects without the syndrome in 
either sex.  eGFR was higher in subjects with 
impaired glucose tolerance than in those without,  but 
not signiﬁcantly.  Glomerular hyperﬁltration exists 
among Japanese type 2 diabetic patients with no evi-
dence of overt proteinuria or hypertension [29].  In 
addition,  according to the analysis of subjects without 
medications,  the link between eGFR and metabolic 
syndrome and its components may be attenuated.  
Therefore,  a signiﬁcant diﬀerence in eGFR between 
subjects with and without metabolic syndrome might 
not be noted.
　 Potential limitations remain in this study.  First,  
our study was a cross sectional and not a longitudinal 
study.  Second,  the 11,711 subjects,  all of whom 
wanted to change their lifestyle,  underwent measure-
ments for this study: they were therefore more health-
conscious than the average person.  The selected 
1,576 subjects underwent fasting blood examination 
and blood pressure measurements and were taking no 
medications; they were therefore more health-con-
scious than most of the subjects in the ﬁrst analysis.  
Although some subjects were within the range of fast-
ing plasma glucose levels at wthich medications are 
recommended,  the prevalence of metabolic syndrome 
in this study was lower than in our previous report 
[7].  This was especially true in women,  only 15 of 
whom were diagnosed as having metabolic syndrome.  
The small sample size in women with metabolic syn-
drome might make it diﬃcult to compare eGFR 
between women with the syndrome and those without.  
Third,  we could not accurately prove the mechanism 
between lower eGFR and metabolic syndrome compo-
nents.  Further prospective studies are needed in 
Japanese subjects using the new Japanese criteria.
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